David Cavalla
Impact in
- Computational Theory and Mathematics top 0.5%
- Computational Drug Discovery Methods
- Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
Papers in
-
- Phosphodiesterase function and regulation 3
-
- Pharmaceutical Economics and Policy 4
- Health Systems, Economic Evaluations, Quality of Life 3
- Co-authors
- Tim Guilliams (2 shared papers)Sudeep Pushpakom (1 shared paper)Francesco Iorio (1 shared paper)Andrew J. Doig (1 shared paper)Christine J. McNamee (1 shared paper)Shirley Hopper (1 shared paper)Patrick A. Eyers (1 shared paper)Joanna Latimer (1 shared paper)
- Journals
- Drug Discovery Today (7 papers)Nature Reviews Drug Discovery (2 papers)European Journal of Pharmacology (2 papers)Journal of Neurochemistry (2 papers)Journal of Pharmacology and Experimental Therapeutics (1 paper)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
David Cavalla
30 papers receiving 3.3k citations
David Cavalla's Hit Papers
Peers
Comparison fields: 5 of 152
- Computational Theory and Mathematics 939
- Infectious Diseases 531
- Molecular Biology 1.6k
- Pharmacology 171
- Biological Psychiatry 41
Countries citing papers authored by David Cavalla
This map shows the geographic impact of David Cavalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cavalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cavalla more than expected).
Fields of papers citing papers by David Cavalla
This network shows the impact of papers produced by David Cavalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cavalla. The network helps show where David Cavalla may publish in the future.
Co-authors
The 25 scholars most cited alongside David Cavalla, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Drug repurposing: progress, challenges and recommendations Hit paper breakdown → | 2018 | 2940 |
| 2 | 1990 | 42 | |
| 3 | 1985 | 41 | |
| 4 | 1985 | 34 | |
| 5 | 2012 | 30 | |
| 6 | 1986 | 28 | |
| 7 | 1985 | 26 | |
| 8 | 2018 | 25 | |
| 9 | 2011 | 22 | |
| 10 | 1985 | 19 | |
| 11 | 2015 | 18 | |
| 12 | 2003 | 17 | |
| 13 | Therapeutic switching: a new strategic approach to enhance R&D productivity. | 2005 | 14 |
| 14 | 2003 | 13 | |
| 15 | 2009 | 13 | |
| 16 | 2019 | 13 | |
| 17 | 1985 | 11 | |
| 18 | 2009 | 10 | |
| 19 | 2022 | 7 | |
| 20 | Adaptations and innovations in drug delivery. | 2001 | 7 |
About David Cavalla
David Cavalla is a scholar working on Molecular Biology, Economics and Econometrics, Pediatrics, Perinatology and Child Health, Cellular and Molecular Neuroscience and Computational Theory and Mathematics, having authored 30 papers that have together received 3.4k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (4 papers), Pharmaceutical studies and practices (4 papers), Neuroscience and Neuropharmacology Research (4 papers), Pharmaceutical Economics and Policy (4 papers), Pharmacogenetics and Drug Metabolism (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Phosphodiesterase function and regulation (3 papers) and Biotechnology and Related Fields (3 papers). The work is most often cited by research in Computational Theory and Mathematics (939 citations), Infectious Diseases (531 citations), Molecular Biology (1.6k citations), Pharmacology (171 citations) and Biological Psychiatry (41 citations). David Cavalla has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Tim Guilliams, Sudeep Pushpakom, Francesco Iorio, Andrew J. Doig, Christine J. McNamee, Shirley Hopper, Patrick A. Eyers, Joanna Latimer, Munir Pirmohamed and Katherine J. Escott. Their work appears in journals such as Drug Discovery Today, Nature Reviews Drug Discovery, European Journal of Pharmacology, Journal of Neurochemistry and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.